Biocon Share Price Target 2025, 2030, 2050

WhatsApp Channel Join Now
Telegram Channel Join Now

Biocon Limited, established in 1978, is a renowned Indian biopharmaceutical business that has advanced globally. One of India’s leading biotechnology companies, Biocon develops and manufactures biosimilars, innovative biologics, and complicated small molecule APIs.

Innovation and affordability in healthcare have made the firm a biopharmaceutical leader.

What is Biocon Industries Ltd NSE: BIOCON?

Bangalore-based Biocon Industries Ltd (NSE: BIOCON) is a significant biopharmaceutical firm. The business does cutting-edge diabetes, cancer, and immunology research. Biocon’s business approach includes biosimilar, new biologic, and branded formulation development. Biocon is a biotechnology powerhouse with a worldwide presence and strategic agreements with major pharmaceutical corporations.

Fundamental Table

MetricValue
Market Cap₹437.60B
P/E Ratio27.68
Dividend Yield0.14%
52-Week High₹395.80
52-Week Low₹217.50

Key Metrics Table

MetricValue
Revenue (TTM)₹34.33B
Net Income (TTM)₹6.60B
EPS (TTM)₹5.31
EBITDA₹5.96B
Debt to EquityNot available

Peers & Comparison Table

CompanyMarket Cap (₹B)P/E Ratio
Biocon437.6027.68
Dr. Reddy’s873.4928.75
Sun Pharma2,549.2636.81
Cipla938.9933.24
Lupin466.9142.17

Biocon Share Price Target Tomorrow

Price TypeMinimumMaximum
Tomororw-7.95+7.80

Biocon Share Price Target 2025

Biocon is a prominent biopharmaceutical brand that researches, develops, and manufactures biosimilars and new biologics. It creates and tests its items internally. Its diverse product line strengthens its market position. Biocon employs nearly 16,000 people using cutting-edge technologies. It aspires to develop inexpensive, high-quality biopharmaceuticals on schedule. In 2025, its share price target would be ₹424, as per our analysis.

By our prediction, its share price would be between ₹276 to ₹424 in 2025.

YearMinimum Price (Rs)Maximum Price (Rs)
2025276424
MonthMinimum Price  (Rs)Maximum Price (Rs)
January347404
February298399
March291354
April288362
May276378
June289380
July298398
August320409
September337415
October355424
November371435
December384444

Biocon Share Price Target 2026

Biocon strengthens its biopharmaceutical market position. Expanding their biosimilar portfolio and entering new areas could boost revenue. Strategic collaborations and R&D expenditures should benefit the organization. Their production capabilities are developing to satisfy demand. In 2026, its share price target would be ₹565, as per our analysis.

By our prediction, its share price would be between ₹384 to ₹565 in 2026.

YearMinimum Price (Rs)Maximum Price (Rs)
2026384565
MonthMinimum Price  (Rs)Maximum Price (Rs)
January384458
February398469
March408481
April421498
May430510
June439519
July451528
August465539
September479545
October484549
November490555
December498565

Share Price Target 2027

In 2027, its share price target would be ₹683, as per our analysis.

By our prediction, its share price would be between ₹498 to ₹683 in 2027.

YearMinimum Price (Rs)Maximum Price (Rs)
2027498683

Share Price Target 2028

In 2028, its share price target would be ₹805, as per our analysis.

By our prediction, its share price would be between ₹653 to ₹805 in 2028.

YearMinimum Price (Rs)Maximum Price (Rs)
2028653805

Share Price Target 2029

In 2029, its share price target would be ₹928, as per our analysis.

By our prediction, its share price would be between ₹775 to ₹928 in 2029.

YearMinimum Price (Rs)Maximum Price (Rs)
2029775928

Biocon Share Price Target 2030

Biocon wants to lead biopharmaceutical innovation worldwide by 2030. With a varied portfolio of biosimilars and new biologics, the business should be robust in key global markets. Their advanced research and development may lead to breakthrough medicines. Biocon’s sustainability and cheap healthcare solutions should appeal globally. In 2030, its share price target would be ₹1052, as per our analysis.

By our prediction, its share price would be between ₹894 to ₹1052 in 2030.

YearMinimum Price (Rs)Maximum Price (Rs)
20308941052

Share Price Target 2040

In 2040, its share price target would be ₹1921, as per our analysis.

By our prediction, its share price would be between ₹1767 to ₹1921 in 2040.

YearMinimum Price (Rs)Maximum Price (Rs)
204017671921

Share Price Target 2050

Biocon is expected to dominate biotechnology and customized medicine by 2050. The company’s long-term investments in genomics, AI in drug development, and sophisticated therapeutics should pay off. Biocon’s dedication to healthcare innovation and accessibility may make it a worldwide health leader. In 2050, its share price target would be ₹3104, as per our analysis.

By our prediction, its share price would be between ₹2912 to ₹3104 in 2050.

YearMinimum Price (Rs)Maximum Price (Rs)
205029123104

Should I buy Biocon stock?

YearMinimum Price (Rs)Maximum Price (Rs)
2025276424
2026384565
2027498683
2028653805
2029775928
20308941052
204017671921
205029123104

Many variables must be considered before investing in Biocon stock. Positive signs include the company’s biosimilar market position, research and development emphasis, and worldwide growth strategy. Investors should also consider biopharmaceutical sector competitiveness and regulatory issues.

Recent quarterly results show Biocon’s strong financial performance, with net income rising significantly. The company’s product expansion and market entry are remarkable. Biocon may appeal to biotechnology investors with a lower P/E ratio of 27.68.

Biocon Industries Ltd Earning Results

Biocon’s latest financial results show outstanding performance and development prospects. In the June 2024 quarter, Biocon reported consolidated sales of ₹34.33 billion, a small year-over-year rise. The net income increased significantly to ₹6.60 billion, suggesting increased profitability.

MetricQ1 FY2025Q1 FY2024YoY Change
Revenue₹34.33B₹34.23B+0.30%
Net Income₹6.60B₹1.01B+550.59%
EPS₹5.31₹0.85+524.58%
EBITDA₹5.96B₹6.30B-5.39%

Expert Forecasts on the Future of Biocon Industries Ltd.

Industry analysts are enthusiastic about Biocon’s future. Analysts expect the company’s biosimilar and new biologic portfolio to fuel growth. Biocon’s worldwide growth, especially in developing countries, is welcomed.

Some analysts expect Biocon will gain from the increased need for inexpensive biopharmaceuticals, particularly in underdeveloped nations. They warn that regulatory clearances, price pressures, and rivalry from established pharmaceutical firms and biosimilar producers may affect the company’s business.

Is Biocon stock good to buy? (Bull case & Bear case)

Bull Case:

  • Strength in biosimilar market growth
  • New solid biologics and biosimilars pipeline
  • Strategic ties with global drugmakers
  • Entry into new markets, especially developing economies
  • Focus on high-growth therapies like diabetes and cancer

Bear Case:

  • Regulatory issues and product clearance delays
  • Biopharmaceutical rivalry is fierce.
  • Potential biosimilar pricing pressures
  • R&D and clinical trial risks
  • Currency fluctuations affect international operations

Conclusion

Biocon Industries Ltd. is a promising long-term biotechnology investment. The company’s excellent foundations, unique product pipeline, and strategic worldwide expansion equip it for growth. Our estimates suggest continuous price appreciation over the next several decades, but longer-term uncertainty increases.

Market variables may cause short-term volatility, but long-term investors may find Biocon appealing for portfolio growth. The company’s adaptability to market changes and investments in future technology may support continued success.

Before investing, you should study and assess your financial objectives and risk tolerance. The dynamic biopharmaceutical business requires diversification and portfolio evaluation to manage investment risks.

FAQs

Biocon develops and manufactures biosimilars, new biologics, and complicated small molecule APIs for diabetes, cancer, and immunology.

Biocon stock has exhibited stability and growth potential, fluctuating from ₹217.50 to ₹395.80 in the previous 52 weeks, indicating corporate performance and market sentiment.

Biosimilar expansion, market penetration, strategic alliances, and high-potential medicinal research and development fuel growth.

Biocon is a major Indian biopharmaceutical company with a competitive P/E ratio. Its emphasis on biosimilars and new biologics sets it apart.

Regulatory issues, biosimilar market rivalry, product approval delays, and pharmaceutical research and development uncertainty are significant hazards.

Similar Stocks